Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 211 AL 225

Cognitive-behavioral treatment for depressed patients with Alzheimer's disease. An open trial

García-Alberca JM.

Arch Gerontol Geriatr. 2017 Jul;71:1-8. doi: 10.1016/j.archger.2017.02.008. Epub 2017 Feb 14.

Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities

Theleritis C, Siarkos K, Katirtzoglou E, Politis A.

J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49. doi: 10.1177/0891988716678684.

The Efficacy of Emotion Recognition Rehabilitation for People with Alzheimer's Disease

García-Casal JA, Goñi-Imizcoz M, Perea-Bartolomé MV, Soto-Pérez F, Smith SJ, Calvo-Simal S, Franco-Martín M.

J Alzheimers Dis. 2017;57(3):937-951. doi: 10.3233/JAD-160940.

Coordinate-Based Meta-Analysis of the Default Mode and Salience Network for Target Identification in Non-Invasive Brain Stimulation of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Networks

Pievani M, Pini L, Ferrari C, Pizzini FB, Boscolo Galazzo I, Cobelli C, Cotelli M, Manenti R, Frisoni GB.

J Alzheimers Dis. 2017;57(3):825-843. doi: 10.3233/JAD-161105.

Late Onset Alzheimer's Disease: Novel Clinical Prospects for the Future

Maiese K.

Curr Neurovasc Res. 2017;14(2):89. doi: 10.2174/1567202614999170313155128.

Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease

Reeves S, McLachlan E, Bertrand J, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R.

Brain. 2017 Apr 1;140(4):1117-1127. doi: 10.1093/brain/aww359.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

Does Functional Connectivity Provide a Marker for Cognitive Rehabilitation Effects in Alzheimer's Disease? An Interventional Study

Ochmann S, Dyrba M, Grothe MJ, Kasper E, Webel S, Hauenstein K, Teipel SJ.

J Alzheimers Dis. 2017;57(4):1303-1313. doi: 10.3233/JAD-160773.

Currents of memory: recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease

Viaña JNM, Vickers JC, Cook MJ, Gilbert F.

Neurobiol Aging. 2017 Aug;56:202-210. doi: 10.1016/j.neurobiolaging.2017.03.001. Epub 2017 Mar 11.

Alzheimer Disease: Monotherapy vs. Combination Therapy

Lawler E, Avila A.

Am Fam Physician. 2017 Apr 1;95(7):452.

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J.

Age Ageing. 2017 Sep 1;46(5):767-773. doi: 10.1093/ageing/afx045.

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

Remyelination: A Potential Therapeutic Strategy for Alzheimer's Disease?

Sun J, Zhou H, Bai F, Zhang Z, Ren Q.

J Alzheimers Dis. 2017;58(3):597-612. doi: 10.3233/JAD-170036.

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

Ahmad J, Akhter S, Rizwanullah M, Khan MA, Pigeon L, Addo RT, Greig NH, Midoux P, Pichon C, Kamal MA.

Curr Alzheimer Res. 2017;14(11):1164-1181. doi: 10.2174/1567205014666170508121031.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias